Literature DB >> 10096290

Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences.

X Li1, E M Eastman, R J Schwartz, R Draghia-Akli.   

Abstract

Relatively low levels of expression from naturally occurring promoters have limited the use of muscle as a gene therapy target. Myogenic restricted gene promoters display complex organization usually involving combinations of several myogenic regulatory elements. By random assembly of E-box, MEF-2, TEF-1, and SRE sites into synthetic promoter recombinant libraries, and screening of hundreds of individual clones for transcriptional activity in vitro and in vivo, several artificial promoters were isolated whose transcriptional potencies greatly exceed those of natural myogenic and viral gene promoters.

Entities:  

Keywords:  NASA Discipline Musculoskeletal; Non-NASA Center

Mesh:

Substances:

Year:  1999        PMID: 10096290     DOI: 10.1038/6981

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  58 in total

Review 1.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

2.  Identification of synthetic endothelial cell-specific promoters by use of a high-throughput screen.

Authors:  Christine Dai; Robin E McAninch; Richard E Sutton
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  Systemic protein delivery by muscle-gene transfer is limited by a local immune response.

Authors:  Lixin Wang; Eric Dobrzynski; Alexander Schlachterman; Ou Cao; Roland W Herzog
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

Review 4.  Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals.

Authors:  David A Dean
Journal:  Am J Physiol Cell Physiol       Date:  2005-08       Impact factor: 4.249

5.  Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments.

Authors:  Carmen Vitiello; Stefania Faraso; Nicolina Cristina Sorrentino; Giovanni Di Salvo; Edoardo Nusco; Gerardo Nigro; Luisa Cutillo; Raffaele Calabrò; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

6.  Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation.

Authors:  Zahra Kadri; Leila Maouche-Chretien; Heather M Rooke; Stuart H Orkin; Paul-Henri Romeo; Patrick Mayeux; Philippe Leboulch; Stany Chretien
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  Correction of glycogenosis type 2 by muscle-specific lentiviral vector.

Authors:  Emmanuel Richard; Gaëlle Douillard-Guilloux; Lionel Batista; Catherine Caillaud
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-09-23       Impact factor: 2.416

Review 8.  Transcriptionally targeted gene therapy to detect and treat cancer.

Authors:  Lily Wu; Mai Johnson; Makoto Sato
Journal:  Trends Mol Med       Date:  2003-10       Impact factor: 11.951

9.  Partial restoration of cardiac function with ΔPDZ nNOS in aged mdx model of Duchenne cardiomyopathy.

Authors:  Yi Lai; Junling Zhao; Yongping Yue; Nalinda B Wasala; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2014-01-25       Impact factor: 6.150

10.  Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation.

Authors:  Philippe Veron; Sylvie Boutin; Samia Martin; Laurence Chaperot; Joel Plumas; Jean Davoust; Carole Masurier
Journal:  J Transl Med       Date:  2009-01-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.